96 related articles for article (PubMed ID: 10822991)
41. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
Amabile M; Giannini B; Testoni N; Montefusco V; Rosti G; Zardini C; Terragna C; Buonamici S; Ottaviani E; Soverini S; Fiacchini M; Bassi S; de Vivo A; Trabacchi E; Saglio G; Pane F; Baccarani M; Tura S; Martinelli G
Haematologica; 2001 Mar; 86(3):252-9. PubMed ID: 11255271
[TBL] [Abstract][Full Text] [Related]
42. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M
J Clin Oncol; 2005 Jun; 23(18):4100-9. PubMed ID: 15867198
[TBL] [Abstract][Full Text] [Related]
43. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
[TBL] [Abstract][Full Text] [Related]
44. Differential display analysis of mRNAs in chronic myelogenous leukaemia.
el-Awady MK; Abdalla NM; Salem AM; Samir S; Nour AM
East Mediterr Health J; 2001; 7(4-5):707-15. PubMed ID: 15332769
[TBL] [Abstract][Full Text] [Related]
45. [Methylation status of id4 gene promoter in patients with chronic myeloid leukemia].
Wang XR; Kang HY; Cen J; Li YH; Wang LL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1402-4. PubMed ID: 21176338
[TBL] [Abstract][Full Text] [Related]
46. [Clinical Study of SCIN Expression and Dromoter Methylation in Patients with Chronic Myeloid Leukemia].
Zhang ZH; Lian XY; Li XX; He PF; Lin J; Qian J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):646-651. PubMed ID: 31204912
[TBL] [Abstract][Full Text] [Related]
47. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
Nguyen TT; Mohrbacher AF; Tsai YC; Groffen J; Heisterkamp N; Nichols PW; Yu MC; Lübbert M; Jones PA
Blood; 2000 May; 95(9):2990-2. PubMed ID: 10779450
[TBL] [Abstract][Full Text] [Related]
48. GPX3 promoter is methylated in chronic myeloid leukemia.
Yao DM; Zhou JD; Zhang YY; Yang L; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Int J Clin Exp Pathol; 2015; 8(6):6450-7. PubMed ID: 26261521
[TBL] [Abstract][Full Text] [Related]
49. Detection of methylated ABL1 promoter in philadelphia-negative myeloproliferative disorders.
Aviram A; Witenberg B; Shaklai M; Blickstein D
Blood Cells Mol Dis; 2003; 30(1):100-6. PubMed ID: 12667992
[TBL] [Abstract][Full Text] [Related]
50. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.
Heller G; Topakian T; Altenberger C; Cerny-Reiterer S; Herndlhofer S; Ziegler B; Datlinger P; Byrgazov K; Bock C; Mannhalter C; Hörmann G; Sperr WR; Lion T; Zielinski CC; Valent P; Zöchbauer-Müller S
Leukemia; 2016 Sep; 30(9):1861-8. PubMed ID: 27211271
[TBL] [Abstract][Full Text] [Related]
51. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
[TBL] [Abstract][Full Text] [Related]
52. Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients.
Mills KI; Guinn BA; Walsh VA; Burnett AK
Leuk Res; 1996 Sep; 20(9):771-5. PubMed ID: 8947587
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.
Koschmieder S; Vetrie D
Semin Cancer Biol; 2018 Aug; 51():180-197. PubMed ID: 28778403
[TBL] [Abstract][Full Text] [Related]
54. Prevention of progression in chronic myeloid leukemia by altering DNA methylation with a pyridoxine analogue.
Sastry PS
Med Hypotheses; 1999 Dec; 53(6):488-9. PubMed ID: 10687889
[TBL] [Abstract][Full Text] [Related]
55. Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia.
Zhou JD; Wang YX; Zhang TJ; Yang DQ; Yao DM; Guo H; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Biochem Biophys Res Commun; 2015 Aug; 463(4):1250-6. PubMed ID: 26086097
[TBL] [Abstract][Full Text] [Related]
56. [Methylation of miR-378 in Chronic Myeloid Leukemia].
Wu DH; Yang J; Yang L; Wen XM; Guo H; Yao DM; Lin J; Zhang YY; Zhang M; Deng ZQ; Qian J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):61-5. PubMed ID: 26913395
[TBL] [Abstract][Full Text] [Related]
57. Aberrant DNA Methylation in Chronic Myeloid Leukemia: Cell Fate Control, Prognosis, and Therapeutic Response.
Behzad MM; Shahrabi S; Jaseb K; Bertacchini J; Ketabchi N; Saki N
Biochem Genet; 2018 Jun; 56(3):149-175. PubMed ID: 29388070
[TBL] [Abstract][Full Text] [Related]
58. The SOCS-1 gene methylation in chronic myeloid leukemia patients.
Hatirnaz O; Ure U; Ar C; Akyerli C; Soysal T; Ferhanoğlu B; Ozçelik T; Ozbek U
Am J Hematol; 2007 Aug; 82(8):729-30. PubMed ID: 17315216
[TBL] [Abstract][Full Text] [Related]
59. SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia.
Wu DL; Wang Y; Zhang TJ; Chu MQ; Xu ZJ; Yuan Q; Ma JC; Lin J; Qian J; Zhou JD
Eur J Med Res; 2022 Nov; 27(1):259. PubMed ID: 36411451
[TBL] [Abstract][Full Text] [Related]
60. [New insight into DNA methylation in CML and its effect on clinical outcome--review].
Tang Y; Hu JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1482-6. PubMed ID: 19099669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
